Abstract
The viral diversity of HIV-1 is likely to require a vaccine strategy that induces broad cellular and humoral anti-HIV-1 immunity. Our strategy is based on multiple HIV-1 DNA immunogens together with adjuvant recombinant granulocyte-macrophage stimulating factor. This article describes pre-clinical and clinical work preceding the initiation of clinical HIV-1 phase I/II trials.
MeSH terms
-
AIDS Vaccines / genetics*
-
AIDS Vaccines / immunology*
-
Animals
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Disease Models, Animal
-
Gene Products, gag / genetics
-
Gene Products, gag / immunology
-
Gene Products, nef / genetics
-
Gene Products, nef / immunology
-
Gene Products, rev / genetics
-
Gene Products, rev / immunology
-
Gene Products, tat / genetics
-
Gene Products, tat / immunology
-
HIV Antigens / genetics*
-
HIV Antigens / immunology*
-
HIV Envelope Protein gp160 / genetics
-
HIV Envelope Protein gp160 / immunology
-
HIV Infections / immunology*
-
HIV Infections / prevention & control
-
HIV Infections / therapy
-
HIV Reverse Transcriptase / genetics
-
HIV Reverse Transcriptase / immunology
-
HIV-1 / genetics
-
HIV-1 / immunology*
-
Humans
-
Leukemia Virus, Murine
-
Mice
-
Mice, Inbred C57BL
-
Vaccines, Combined / genetics
-
Vaccines, Combined / immunology
-
Vaccines, DNA / genetics
-
Vaccines, DNA / immunology*
-
nef Gene Products, Human Immunodeficiency Virus
-
rev Gene Products, Human Immunodeficiency Virus
-
tat Gene Products, Human Immunodeficiency Virus
Substances
-
AIDS Vaccines
-
Gene Products, gag
-
Gene Products, nef
-
Gene Products, rev
-
Gene Products, tat
-
HIV Antigens
-
HIV Envelope Protein gp160
-
Vaccines, Combined
-
Vaccines, DNA
-
nef Gene Products, Human Immunodeficiency Virus
-
rev Gene Products, Human Immunodeficiency Virus
-
tat Gene Products, Human Immunodeficiency Virus
-
HIV Reverse Transcriptase